XELJANZ 11 mg, extended-release tablet 28 tablets
Active ingredients: Tofacitinib citrate, Tofacitinib
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- XELJANZ 11 mg, comprimé à libération prolongée
- Pharmaceutical form
- comprimé à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) aluminium PVC-Aluminium de 28 comprimés
- Marketing authorisation holder
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 4 Jan 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66610933CIP73019989CIP133400930199893Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TOFACITINIBcomprimé | 11 mg · un comprimé | FT |
| CITRATE DE TOFACITINIBcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.